Life Sciences Future brings together the brightest and most innovative minds – and matches them with striking and engaging content and interactive sessions.

Day One Keynote - Dr. Epstein

Jonathan A. Epstein, M.D.

Executive Vice Dean and Chief Scientific Officer
William Wikoff Smith Professor of Medicine
Perelman School of Medicine
University of Pennsylvania


Dr. Epstein graduated from Harvard College in 1983, Harvard Medical School in 1988 and completed his Residency and Fellowship in Medicine and Cardiology at the Brigham and Women’s Hospital, where he also completed an HHMI Postdoctoral Fellowship in Genetics. In 1996 he accepted a position as Assistant Professor of Medicine in the Division of Cardiology at the University of Pennsylvania. From 2006-2015, he served as Chairman of the Department of Cell and Developmental Biology and Scientific Director of the Penn Cardiovascular Institute.  He is currently the William Wikoff Smith Professor, Executive Vice Dean and Chief Scientific Officer at the Perelman School of Medicine at the University of Pennsylvania.

Felix Hsu - Wuxi

Felix Hsu

Senior Vice President, Head of US Business Unit, WuXi AppTec


Felix Hsu has led the WuXi AppTec U.S. Business Unit for over eight years. WuXi has provided cell therapy manufacturing since 2004, and over the last 4-5 years has invested significantly in building out manufacturing capabilities for Advanced Therapies which include cell and gene therapy. Felix’s career also includes over 20 years of experience in the medical device and pharmaceutical industries including roles as the VP for Global Supply Chain and the GM for Cardiac Surgery in Asia Pacific at Medtronic.

Jeff Marrazzo_color_1_headshot

Jeffrey D. Marrazzo

Chief Executive Officer, Spark Therapeutics


Jeff Marrazzo has led the creation and growth of Spark Therapeutics from a research center within the Children’s Hospital of Philadelphia to a fully integrated gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now. He also serves on Spark Therapeutics’ board of directors.


Adrian Rawcliffe

Chief Financial Officer, AdaptImmune


Adrian Rawcliffe has served as our Chief Financial Officer since March 2015 and leads our financial strategy and operations, as well as Investor Relations, corporate communications, global IT and facilities. He has 17 years of experience within the pharmaceutical industry and most recently served as Senior Vice President, Finance of GSK’s North American Pharmaceuticals business. Mr. Rawcliffe currently serves as a non-executive director of WAVE Life Sciences (NASDAQ: WVE).

The Details

Life Sciences Future
September  18 + 19, 2017
Philadelphia Marriott Downtown
Philadelphia, PA 19107